| Title: |
Raloxifene augmentation in men and women with a schizophrenia spectrum disorder:A study protocol |
| Authors: |
Brand, Bodyl A.; de Boer, Janna N.; Ophuis, Sebastianus B. J. Oude; Slot, Margot I. E.; De Wilde, Bieke; Catthoor, Kirsten C. E. E. R.; Goverde, Angelique J.; Bakker, P. Roberto; Marcelis, Machteld C.; Grootens, Koen P.; Luykx, Jurjen J.; Heringa, Sophie M.; Weickert, Cynthia Shannon; Sommer, Iris E. C.; Weickert, Thomas W. |
| Source: |
Brand , B A , de Boer , J N , Ophuis , S B J O , Slot , M I E , De Wilde , B , Catthoor , K C E E R , Goverde , A J , Bakker , P R , Marcelis , M C , Grootens , K P , Luykx , J J , Heringa , S M , Weickert , C S , Sommer , I E C & Weickert , T W 2020 , ' Raloxifene augmentation in men and women with a schizophrenia spectrum disorder : A study .... |
| Publication Year: |
2020 |
| Subject Terms: |
Antipsychotic medication; Estrogen; Raloxifene; Randomised controlled trial; Schizophrenia; POSTMENOPAUSAL WOMEN; PERSISTENT SYMPTOMS; NEGATIVE SYNDROME; SEX-DIFFERENCES; DOUBLE-BLIND; SCALE; COGNITION; RELIABILITY; PERFORMANCE; psy; socio |
| Description: |
Although acute psychotic symptoms are often reduced by antipsychotic treatment, many patients with schizophrenia are impaired in daily functioning due to the persistence of negative and cognitive symptoms. Raloxifene, a Selective Estrogen Receptor Modulator (SERM) has been shown to be an effective adjunctive treatment in schizophrenia. Yet, there is a paucity in evidence for raloxifene efficacy in men and premenopausal women. We report the design of a study that aims to replicate earlier findings concerning the efficacy of raloxifene augmentation in reducing persisting symptoms and cognitive impairment in postmenopausal women, and to extend these findings to a male and peri/premenopausal population of patients with schizophrenia. The study is a multisite, placebo-controlled, double-blind, randomised clinical trial in approximately 110 adult men and women with schizophrenia. Participants are randomised 1:1 to adjunctive raloxifene 120 mg or placebo daily during 12 weeks. The treatment phase includes measurements at three time points (week 0, 6 and 12), followed by a follow-up period of two years. The primary outcome measure is change in symptom severity, as measured with the Positive and Negative Syndrome Scale (PANSS), and cognition, as measured with the Brief Assessment of Cognition in Schizophrenia (BACS). Secondary outcome measures include social functioning and quality of life. Genetic, hormonal and inflammatory biomarkers are measured to assess potential associations with treatment effects. If it becomes apparent that raloxifene reduces psychotic symptoms and/or improves cognition, social functioning and/or quality of life as compared to placebo, implementation of raloxifene in clinical psychiatric practice can be considered. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://pure.rug.nl/ws/files/160318123/Raloxifene_augmentation_in_men_and_women_with_a_schizophrenia_spectrum_disorder_A_study_protocol.pdf; https://hdl.handle.net/11370/2161c306-46c6-4ef3-8b97-71f95e78fd2d |
| Availability: |
https://pure.rug.nl/ws/files/160318123/Raloxifene_augmentation_in_men_and_women_with_a_schizophrenia_spectrum_disorder_A_study_protocol.pdf; https://hdl.handle.net/11370/2161c306-46c6-4ef3-8b97-71f95e78fd2d |
| Rights: |
undefined |
| Accession Number: |
edsbas.8FD254CD |
| Database: |
BASE |